Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

2 evidence topics · 1 source

Nonclinical pharmacology

“These studies evaluate the efficacy and safety profile of Saroglitazar in preclinical in vitro and in vivo models.” (opens the source at this quote in a new tab)

Preclinical PPAR transactivation assay in HepG2 cells

Receptor	Saroglitazar EC50
hPPARα	“0.65 pmol/L”
hPPARγ	“3 nmol/L”